**Supplement Table 1: Treatment compliance in the safety set**

|  | SPP-003 n (%) | Placebo n (%) | Total n (%) |
| --- | --- | --- | --- |
| n | 35 | 39 | 74 |
| Compliance in the period of primary assessment (%) |  |  |  |
| Mean ± SD | 94.23 ± 14.18 | 94.93 ± 15.39 | 94.60 ±14.73 |
| Median [Minimum, Maximum] | 100.00 [51.1, 100.0] | 100.00 [23.1, 100.0] | 100.00 [23.1, 100.0] |
|  |  |  |  |
| Compliance in the study drug administration period (%) |  |  |  |
| Mean ± SD | 95.20 ± 11.13 | 93.81 ± 15.56 | 94.47 ± 13.57 |
| Median [Minimum, Maximum] | 99.57 [51.7, 100.0] | 99.45 [23.1, 100.0] | 99.47 [23.1, 100.0] |
|  |  |  |  |
| Period of primary assessment: |  |  |  |
| Non-compliant subjects (1) | 5 (14.3) | 3 (7.7) | 8 (10.8) |
| Overdose subjects (2) | 0 | 0 | 0 |
|  |  |  |  |
| Study drug administration period: |  |  |  |
| Non-compliant subjects (1) | 3 (8.6) | 3 (7.7) | 6 (8.1) |
| Overdose subjects (2) | 0 | 0 | 0 |

Percentages are calculated using the number of subjects in the safety set as the denominator.

For the period of primary assessment, if the date of day 22 in course one is missing, then the date was substituted by that of day 1 in course 1 + 21.

Noncompliance was defined as <80% compliance. Overdose was defined as >100% compliance.